Mankind Pharma has received the licence to manufacture and market oral 2-deoxy-D-glucose (2-DG) from Defence Research and Development Organisation (DRDO), the company said on Thursday. The drug is used for the treatment of COVID-19.
It will manufacture the product at its facilities in Visakhapatnam and Himachal Pradesh, it added.
The office of the Drugs Controller General of India (DCGI) on May 1 had permitted the emergency use of 2-DG as an adjunct treatment for moderate to severe COVID-19 patients, Mankind Pharma said.
Bajaj Healthcare Limited (BHL) also announced that it has received license from DRDO to manufacture 2-DG drug used in control and treatment of Covid-19.
Recently, a new study has claimed that DRDO’s anti-COVID drug 2-DG is effective against all variants of COVID-19 and the drug reduces virus multiplication.
The study, published on June 15, has not yet been peer-reviewed. It was conducted by Annat Narayan Bhatt, Abhishek Kumar, Yogesh Rai, Dhiviya Vedagiri and others.
